Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman Sells 1,520 Shares

Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares of the company’s stock, valued at approximately $5,708,568.04. This trade represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Glaukos Stock Performance

NYSE GKOS traded up $0.54 during trading on Thursday, reaching $103.67. The company’s stock had a trading volume of 426,365 shares, compared to its average volume of 585,418. The firm has a 50 day moving average price of $131.61 and a 200 day moving average price of $135.83. Glaukos Co. has a 12 month low of $88.16 and a 12 month high of $163.71. The firm has a market capitalization of $5.86 billion, a price-to-earnings ratio of -36.12 and a beta of 0.99. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The company had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. As a group, equities analysts anticipate that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Wells Fargo & Company upped their target price on shares of Glaukos from $153.00 to $160.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Piper Sandler restated an “overweight” rating and issued a $180.00 target price (up previously from $140.00) on shares of Glaukos in a research note on Monday, January 27th. Needham & Company LLC increased their price objective on shares of Glaukos from $149.00 to $176.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Mizuho raised shares of Glaukos from a “neutral” rating to an “outperform” rating and raised their target price for the company from $140.00 to $200.00 in a research note on Wednesday, February 19th. Finally, Stifel Nicolaus upped their price objective on Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, December 31st. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and an average target price of $163.25.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. California State Teachers Retirement System grew its stake in Glaukos by 7.2% during the fourth quarter. California State Teachers Retirement System now owns 50,949 shares of the medical instruments supplier’s stock worth $7,639,000 after buying an additional 3,409 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Glaukos during the 4th quarter worth approximately $12,367,000. Forum Financial Management LP bought a new position in Glaukos in the fourth quarter valued at approximately $211,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Glaukos by 20.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 162,326 shares of the medical instruments supplier’s stock valued at $24,339,000 after purchasing an additional 27,889 shares in the last quarter. Finally, State of Wyoming lifted its stake in Glaukos by 2.3% during the fourth quarter. State of Wyoming now owns 3,245 shares of the medical instruments supplier’s stock worth $487,000 after purchasing an additional 72 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.